K Fizazi

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. doi request reprint Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    Karim Fizazi
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Lancet Oncol 13:983-92. 2012
  2. ncbi request reprint Novel and bone-targeted agents for CRPC
    K Fizazi
    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif 94800, France
    Ann Oncol 23:x264-7. 2012
  3. ncbi request reprint [Prostate cancer: future strategies for chemotherapy management]
    K Fizazi
    Institut Gustave Roussy, 14, avenue Paul Vaillant Couturier, 94800 Villejuif, France
    Ann Urol (Paris) 41:S77-9. 2007
  4. doi request reprint The postchemotherapy PSA surge syndrome
    R Thuret
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 19:1308-11. 2008
  5. doi request reprint [New drugs in metastatic castration-resistant prostate cancer]
    L Albiges
    Institut Gustave Roussy, Departement de Medecine, 39 rue Camille Desmoulins, 94800 Villejuif, France
    Bull Cancer 97:149-59. 2010
  6. doi request reprint Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
    S Rajpar
    Department of Medicine, Institut Gustave Roussy, University of Paris XI, Villejuif, France
    Ann Oncol 21:1864-9. 2010
  7. ncbi request reprint Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes
    L Zelek
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:1265-8. 2001
  8. doi request reprint Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
    K Fizazi
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Eur J Cancer 48:85-93. 2012
  9. doi request reprint Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
    R De Crevoisier
    Department of Radiation, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:808-14. 2010
  10. doi request reprint Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors
    C Massard
    Department of Medical Oncology, Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Ann Oncol 24:322-8. 2013

Detail Information

Publications60

  1. doi request reprint Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    Karim Fizazi
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Lancet Oncol 13:983-92. 2012
    ..Here, we present the final analysis of the study before crossover from placebo to abiraterone acetate (after 775 of the prespecified 797 death events)...
  2. ncbi request reprint Novel and bone-targeted agents for CRPC
    K Fizazi
    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif 94800, France
    Ann Oncol 23:x264-7. 2012
    ..benefit? Can we personalise treatment based on the biology of the individual's disease? How will we develop new active compounds in the context where a half dozen approved agents may confound their potential overall survival effect?..
  3. ncbi request reprint [Prostate cancer: future strategies for chemotherapy management]
    K Fizazi
    Institut Gustave Roussy, 14, avenue Paul Vaillant Couturier, 94800 Villejuif, France
    Ann Urol (Paris) 41:S77-9. 2007
    ..The docetaxel plus estramustine association is likely more active than docetaxel alone. Docetaxel is currently tested in early stages: first results of phase III trials are expected by 2009-2010...
  4. doi request reprint The postchemotherapy PSA surge syndrome
    R Thuret
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 19:1308-11. 2008
    ..The objective of this work was to study early serum PSA changes in patients under chemotherapy and to correlate these changes with subsequent response assessment...
  5. doi request reprint [New drugs in metastatic castration-resistant prostate cancer]
    L Albiges
    Institut Gustave Roussy, Departement de Medecine, 39 rue Camille Desmoulins, 94800 Villejuif, France
    Bull Cancer 97:149-59. 2010
    ..A recent analogue of thalidomide, probably more efficient, lenalidomide is also in development...
  6. doi request reprint Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
    S Rajpar
    Department of Medicine, Institut Gustave Roussy, University of Paris XI, Villejuif, France
    Ann Oncol 21:1864-9. 2010
    ..The aim of this study was to assess the prognostic value of uNTx for overall survival (OS) and the incidence of SRE in patients with bone metastases from CRPC receiving zoledronic acid...
  7. ncbi request reprint Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes
    L Zelek
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:1265-8. 2001
    ..The aim of the study was to assess its tolerance and efficacy in advanced breast cancer after failure with usual regimens...
  8. doi request reprint Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
    K Fizazi
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Eur J Cancer 48:85-93. 2012
    ....
  9. doi request reprint Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
    R De Crevoisier
    Department of Radiation, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:808-14. 2010
    ..In group 2, PSA was measured again 3 months after the start of ADT, before EBRT (PSA(ADT-preRT))...
  10. doi request reprint Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors
    C Massard
    Department of Medical Oncology, Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Ann Oncol 24:322-8. 2013
    ..The aim of this study was to assess whether a TM decline (TMD) also correlates with the outcome in the salvage setting...
  11. ncbi request reprint Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse
    J Alexandre
    Department of Medicine, Institut Gustave Roussy, 94805, Villejuif Cedex, France
    Eur J Cancer 37:576-82. 2001
    ..Patients who belong to this subgroup should be managed by surveillance only, instead of retroperitoneal lymph node dissection (RPLND) or adjuvant chemotherapy...
  12. ncbi request reprint Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy
    K Fizazi
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 16:725-32. 1998
    ..We describe the clinical and biologic features of these patients and evaluate the results of treatment during the cisplatin era...
  13. ncbi request reprint Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma
    L Zelek
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Cancer 92:2267-72. 2001
    ..The objective of the study was to assess the tolerance and efficiency of weekly vinorelbine in metastatic breast carcinoma after failure with taxanes...
  14. doi request reprint Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
    Y Loriot
    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, INSERM 981, Villejuif, France
    Ann Oncol 24:1807-12. 2013
    ..The antitumour activity of abiraterone and prednisolone in patients pre-treated with enzalutamide is as yet unknown...
  15. ncbi request reprint How to select amongst available options for the treatment of advanced RCC?
    B Escudier
    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif 94800, France
    Ann Oncol 23:x309-12. 2012
    ..The different options are described in this manuscript...
  16. doi request reprint Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
    Y Loriot
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 20:703-8. 2009
    ..The purpose of this study was to prospectively assess the anticancer activity and tolerance of the carboplatin-etoposide combination in this setting while evaluating neuroendocrine (NE) features...
  17. doi request reprint Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial
    M Gross-Goupil
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Eur J Cancer 48:721-7. 2012
    ..To compare the overall survival rates of good-prognosis carcinomas of an unknown primary site (CUPS) patients treated with cisplatin alone (C) or in combination with gemcitabine (CG)...
  18. ncbi request reprint Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer
    K Fizazi
    Institut Gustave Roussy, Villejuif, and AstraZeneca Pharmaceuticals, Cergy, France
    J Clin Oncol 18:2293-300. 2000
    ....
  19. doi request reprint Recent developments in treatments targeting castration-resistant prostate cancer bone metastases
    Y Loriot
    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Ann Oncol 23:1085-94. 2012
    ..Materials and methods: Relevant studies of CRPC and targeted therapies were identified from literature and clinical trial databases, websites, and conference abstracts...
  20. doi request reprint [Prognosis and predictive factors in prostate cancer]
    L Albiges-Sauvin
    Institut Gustave Roussy, 39 bis, rue Camille Desmoulins, 94800 Villejuif, France
    Bull Cancer 96:439-49. 2009
    ....
  21. doi request reprint Incidence of brain metastases in renal cell carcinoma treated with sorafenib
    C Massard
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:1027-31. 2010
    ..i.d.), versus placebo in the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET)...
  22. ncbi request reprint Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group
    K Fizazi
    Institut Gustave Roussy, Villejuif, Centre Leon Berard, Lyon, and Centre Val d Aurelle, Montpellier, France
    J Clin Oncol 19:2647-57. 2001
    ..To assess the value of postsurgery chemotherapy in patients with disseminated nonseminomatous germ-cell tumors (NSGCTs) and viable residual disease after first-line cisplatin-based chemotherapy...
  23. ncbi request reprint Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study
    M Saghatchian
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:535-40. 2001
    ..To evaluate the efficacy and toxicity of a chemotherapy strategy based on histological differentiation, for patients with carcinoma of unknown primary site...
  24. doi request reprint A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors
    C Theodore
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 19:1465-9. 2008
    ..The aim of this study is to determine feasibility and efficacy of the combination regimen oxaliplatin and paclitaxel in patients with cisplatin (CDDP)-refractory germ-cell tumors (GCT)...
  25. ncbi request reprint Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
    C Massard
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:1585-8. 2010
    ..The management of these patients was modified at Institut Gustave Roussy in 1997 to try to avoid this complication...
  26. ncbi request reprint Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients
    K Fizazi
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 16:3736-43. 1998
    ..To assess the outcome and the prognosis of adults with a neoplasm related to the Ewing's sarcoma family of tumors...
  27. doi request reprint How to select targeted therapy in renal cell cancer
    B Escudier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:vii59-62. 2010
    ..In addition, in front of every patient, the physician will need to raise important questions such as whether the patient should be treated, should receive surgery and also what is his prognosis. The different options are described here...
  28. doi request reprint Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors
    T Bessede
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 22:2320-4. 2011
    ..The objective of the study was to investigate possible sexual disorders in a male population with advanced RCC treated with a molecular targeted therapy (MTT)...
  29. ncbi request reprint Is òne cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 11:133-49. 2000
    ..Our objective was to assess the clinical relevance of the rapid repetition of regimens (so-called 'dose-dense chemotherapy') in various solid neoplasms...
  30. pmc Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
    C Massard
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France
    Br J Cancer 97:857-61. 2007
    ..This finding may prompt clinical trials investigating EGFR inhibitors in this setting. In contrast, c-Kit expression and Her-2/neu overexpression occur infrequently in CUP. EGFR expression was correlated to tumour chemosensitivity...
  31. ncbi request reprint Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800, Villejuif, France
    Eur J Cancer 36:1514-21. 2000
    ..The efficacy/toxicity ratio of this combination compares favourably with that of our previous chemotherapy and chemo-immunotherapy regimens...
  32. ncbi request reprint A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial
    K Fizazi
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Ann Oncol 13:125-34. 2002
    ....
  33. pmc Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours
    K Fizazi
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Br J Cancer 86:1555-60. 2002
    ..Because outcomes with this regimen compare favourably with outcome after standard therapy, dose-dense chemotherapy should be further investigated in this subset of patients...
  34. ncbi request reprint Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Int J Gynecol Cancer 12:749-54. 2002
    ..Median overall survival was 14 month overall, 45 months for Group 1 and 13 months for Group 2. We conclude that the DECAV regimen is clearly active in uterine sarcomas but is too toxic to be recommended routinely...
  35. pmc Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy
    Ch Theodore
    Department of Medicine, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94800 Villejuif, France
    Br J Cancer 90:55-9. 2004
    ..Therapeutic indications for synchronous BGCT, including conservative treatment, need to be better defined...
  36. ncbi request reprint Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 21:349-54. 2003
    ..Most patients (66%) had advanced disease. Patients received raltitrexed 3 mg/m2 followed by oxaliplatin 130 mg/m2 every 3 weeks...
  37. ncbi request reprint Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial
    K Fizazi
    Department of Cancer Medicine, Institut Gustave Roussy, Villejuif
    Ann Oncol 25:987-91. 2014
    ..As gemcitabine consistently displayed activity in patients with advanced GCT and as synergy with cisplatin was reported, we integrated this drug into the salvage triplet regimen and assessed its activity in this phase II study...
  38. ncbi request reprint Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 19:259-64. 2008
    ..The purpose of this study was to validate a prognostic index [surgical complete response 1 (sCR1)] in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT)...
  39. ncbi request reprint High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:518-21. 2007
    ..Telomerase activation, one of the major immortalization events, is found in most cases of prostate cancer. We attempted to develop a method using telomerase activity to isolate CTCs in patients with prostate cancer...
  40. pmc Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumours
    K Fizazi
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 75:76-8. 1997
    ..However, normalization is frequently associated with an improvement of symptoms or a moderate clinical response...
  41. pmc The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area
    A C Piketty
    Institut Gustave Roussy, Villejuif, France
    Br J Cancer 93:909-14. 2005
    ..This risk can be accurately predicted by serum LDH and body surface area. This predictive index may help to study prospectively the impact of thromboprophylaxis in GCT patients...
  42. ncbi request reprint Germ cell tumors in patients infected by the human immunodeficiency virus
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Cancer 92:1460-7. 2001
    ..The objective of this study was to assess the natural history of the two disease courses, patient immune system tolerance, and results of therapy in human immunodeficiency virus (HIV)-infected patients with germ cell tumors (GCT)...
  43. ncbi request reprint The role of Src in prostate cancer
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France
    Ann Oncol 18:1765-73. 2007
    ..Src inhibitors may be specifically evaluated in prostate cancer clinical trials in the near future...
  44. doi request reprint Non-germ cell tumours arising in germ cell tumours (teratoma with malignant transformation) in men: CT and MR findings
    A Athanasiou
    Department of Radiology, Institut Gustave Roussy, Villejuif, France
    Eur J Radiol 69:230-5. 2009
    ..To describe the imaging findings of germ cell tumours (GCT) containing non-germ cell malignant components (also designated teratoma with malignant transformation or TMT)...
  45. ncbi request reprint Acute respiratory distress syndrome after chemotherapy for lung metastases from non-seminomatous germ-cell tumors
    C Kirch
    Service de Reanimation Polyvalente, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Support Care Cancer 11:575-80. 2003
    ....
  46. ncbi request reprint Association between germ cell tumours, large numbers of naevi, atypical naevi and melanoma
    M F Avril
    Department of Dermatology, Institut Gustave Roussy, Villejuif, France
    Melanoma Res 11:117-22. 2001
    ..Patients harbouring multiple pigmented spots should be referred for a skin examination aimed at early detection of curable melanomas, and should be advised to protect themselves from sun exposure...
  47. ncbi request reprint A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract
    C Theodore
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:990-4. 2006
    ..The aim of the study was to evaluate the activity and the safety of the gemcitabine-oxaliplatin (GEMOX) combination as first-line treatment in advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract...
  48. ncbi request reprint Treatment of patients with specific subsets of carcinoma of an unknown primary site
    K Fizazi
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:x177-80. 2006
  49. ncbi request reprint [Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer]
    M Ducreux
    , Institut Gustave-Roussy, rue Camille-Desmoulins, 94805 Villejuif Cedex
    Bull Cancer 88:S35-9. 2001
    ..The dose intensity was maintained with the use of hematopoietic growth factors. These new combinations with oxaliplatin give us the opportunity to treat the patient with schedules excluding fluorouracil which has a variable metabolism...
  50. ncbi request reprint Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors
    J T Hartmann
    Medical Center II, EberhardKarls-University Tuebingen, Germany
    J Natl Cancer Inst 93:1733-8. 2001
    ..2%; 95% CI = 0.1% to 12.2%). CONCLUSIONS: Patients with EGCTs, particularly those with retroperitoneal or nonseminomatous tumors, but also those with primary mediastinal EGCTs, are at an increased risk of metachronous testicular cancer...
  51. ncbi request reprint Carcinomas of an unknown primary site: a curable disease?
    A Levy
    Ann Oncol 19:1657-8. 2008
  52. ncbi request reprint Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)
    S Culine
    CRLC Val d Aurelle, Montpellier, France
    Ann Oncol 18:917-24. 2007
    ..High cure rates are expected in good-risk metastatic nonseminomatous germ-cell tumor (NSGCT) patients with bleomycin, etoposide and cisplatin...
  53. ncbi request reprint European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
    H J Schmoll
    European Germ Cell Cancer Consensus Group, Martin Luther University, Department of Hematology Oncology, Halle, Germany
    Ann Oncol 15:1377-99. 2004
    ..Since this guideline is based on the highest evidence level available today, a deviation from these proposals should be a rare and justified exception...
  54. ncbi request reprint Germ-cell tumor survivors: the price for cure
    K Fizazi
    Ann Oncol 13:187-9. 2002
  55. ncbi request reprint Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of
    J P Lotz
    Department of Medical Oncology, Hopital Tenon, Paris, France
    Ann Oncol 16:411-8. 2005
    ..High-dose chemotherapy (HD-CT) is able to circumvent platinum resistance of resistant/refractory germ-cell tumors (GCTs), but expectancy of cure remains low. New strategies are needed with new drugs and a sequential approach...
  56. ncbi request reprint Oxaliplatin in non-seminomatous germ-cell tumors
    K Fizazi
    Ann Oncol 15:1295. 2004
  57. pmc Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients
    N Ady
    CEA, Laboratoire de Radiobiologie et Oncologie, DRR DSV, 92265 Fontenay aux Roses, France
    Br J Cancer 90:443-8. 2004
    ..The present method appears to be minimally invasive, highly sensitive and a specific approach for detecting CTCs in PC. Furthermore, it may help better target HER-2/neu in advanced PC...
  58. ncbi request reprint [Difficult clinical cases in prostate cancer: multidisciplinary staff, the rational principles of adjuvant therapy and other therapeutic options]
    M Zerbib
    Service d Urologie, Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Ann Urol (Paris) 40:S35-41. 2006
    ..Immediate hormonal therapy with bicalutamide is a valuable therapeutic option in men having prostate cancer with such clinicopathological features...
  59. pmc Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)
    R Bugat
    Institut Claudius Regaud, Toulouse, France
    Br J Cancer 89:S59-66. 2003
  60. ncbi request reprint Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway
    J Yang
    Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 61:5652-9. 2001
    ..Moreover, it allows to screen for therapeutic agents blocking the osteoblast response to prostate cancer...